Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Masitinib: a first-in-class TKI as treatment of progressive MS Next Article
Modulating BTK-dependent inflammatory signalling in microglia »
« Masitinib: a first-in-class TKI as treatment of progressive MS Next Article
Modulating BTK-dependent inflammatory signalling in microglia »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
December 16, 2020
Characteristics of a population-based MS cohort treated with DMDs
September 10, 2020
Alemtuzumab efficacy and safety data of over 9 years
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy